Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
EZH2
NSD2
prognosis
progression
triple-negative breast cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
08
2020
accepted:
29
12
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Two histone methyltransferases, enhancer of zeste homolog 2 (EZH2) and nuclear SET domain-containing 2 (NSD2), are aberrantly expressed in several types of human cancers. However, the regulatory relationship between EZH2 and NSD2 and their prognostic values in breast cancer (BC) have not been fully elucidated. In this study, we demonstrated that EZH2 and NSD2 were overexpressed in BC compared with benign lesions and normal tissues using tissue microarray, immunohistochemistry, and bioinformatic databases. Both EZH2 and NSD2 expression were associated with pathological grade of tumor and lymph node metastasis. A comprehensive survival analysis using Kaplan-Meier Plotter database indicated that EZH2 expression was negatively correlated with relapse-free survival (RFS), overall survival (OS), distant metastasis-free survival (DMFS), and postprogression survival (PPS) in 3951 BC patients, and NSD2 expression was negatively correlated with RFS and DMFS. Notably, EZH2 and NSD2 expression were coordinately higher in triple-negative breast cancer (TNBC) than that in other subtypes. Stable knockdown of EZH2 using lentiviral shRNA vector significantly reduced the proliferation, migration and invasion abilities of TNBC cell line MDA-MB-231 and MDA-MB-468, and downregulated NSD2 expression as well as the levels of H3K27me3 and H3K36me2, two histone methylation markers catalyzed by EZH2 and NSD2, respectively. By contrast, overexpression of EZH2 using adenovirus vector displayed an inverse phenotype. Furthermore, knockdown of NSD2 in EZH2-overexpressing cells could dramatically attenuate EZH2-mediated oncogenic effects. Bioinformatic analysis further revealed the function and pathway enrichments of co-expressed genes and interactive genes of EZH2/NSD2 axis, suggesting that EZH2/NSD2 axis was associated with cell division, mitotic nuclear division and transition of mitotic cell cycle in TNBC. Taken together, EZH2/NSD2 axis may act as a predictive marker for poor prognosis and accelerate the progression of TNBC.
Identifiants
pubmed: 33665162
doi: 10.3389/fonc.2020.600514
pmc: PMC7921704
doi:
Types de publication
Journal Article
Langues
eng
Pagination
600514Informations de copyright
Copyright © 2021 Gao, Liu, Li, Zhao and Pan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biomark Res. 2018 Dec 7;6:34
pubmed: 30555699
Cancer Lett. 2016 Aug 10;378(2):69-79
pubmed: 27164560
Cancer Res. 2014 Jul 15;74(14):3870-9
pubmed: 24802190
Int J Biol Sci. 2017 May 16;13(5):652-659
pubmed: 28539837
Mol Cell. 2013 Jan 10;49(1):80-93
pubmed: 23159737
World J Gastroenterol. 2003 Dec;9(12):2863-5
pubmed: 14669354
Biochem Biophys Res Commun. 2014 Sep 26;452(3):642-8
pubmed: 25193695
Oncotarget. 2015 Sep 29;6(29):27023-36
pubmed: 26304929
Front Immunol. 2016 May 03;7:172
pubmed: 27199994
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Biomed Res Int. 2014;2014:636514
pubmed: 25093175
Cancer Biol Ther. 2020 Jun 2;21(6):533-540
pubmed: 32175798
J Cell Biol. 2008 Mar 10;180(5):915-29
pubmed: 18332217
Pharmacol Ther. 2016 Sep;165:26-31
pubmed: 27179746
Cancer Res Treat. 2019 Jul;51(3):1207-1221
pubmed: 30590004
Enzymes. 2016;39:231-54
pubmed: 27241932
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
pubmed: 14500907
Sci Rep. 2016 Sep 08;6:32952
pubmed: 27604143
World J Biol Chem. 2015 Nov 26;6(4):346-50
pubmed: 26629317
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8324-8333
pubmed: 31966683
Cancer Sci. 2018 Aug;109(8):2342-2348
pubmed: 29845708
Folia Neuropathol. 2019;57(1):6-15
pubmed: 31038183
Onco Targets Ther. 2020 Jul 20;13:7033-7044
pubmed: 32801739
Nat Commun. 2018 Dec 5;9(1):5201
pubmed: 30518758
Int J Mol Sci. 2017 May 31;18(6):
pubmed: 28561778
Am J Pathol. 2009 Sep;175(3):1246-54
pubmed: 19661437
Med Sci Monit. 2018 Dec 29;24:9442-9464
pubmed: 30593585
Cancer. 2011 Dec 15;117(24):5476-84
pubmed: 21713757
Cancer Manag Res. 2018 Jan 15;10:91-103
pubmed: 29391830
Future Oncol. 2018 Apr;14(8):709-718
pubmed: 29323532
Biomark Res. 2018 Mar 9;6:10
pubmed: 29556394
Cell Death Dis. 2019 Jan 25;10(2):65
pubmed: 30683853
Acta Biochim Biophys Sin (Shanghai). 2018 Sep 1;50(9):897-904
pubmed: 30060056
Oncotarget. 2017 Sep 8;8(54):92106-92118
pubmed: 29190901
Lancet Oncol. 2014 Jun;15(7):e279-89
pubmed: 24872111
Front Immunol. 2014 Nov 19;5:596
pubmed: 25477884
Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):587-597
pubmed: 29408056
Acta Pharmacol Sin. 2019 Aug;40(8):1067-1075
pubmed: 30670815
Mol Cell. 2011 Nov 18;44(4):609-20
pubmed: 22099308
J Pathol. 2019 May;248(1):103-115
pubmed: 30666650
Aging (Albany NY). 2020 May 4;12(9):8372-8396
pubmed: 32365332
Int J Biol Sci. 2012;8(1):59-65
pubmed: 22211105
Cancer Manag Res. 2020 Jan 16;12:375-383
pubmed: 32021450
Breast Cancer Res Treat. 2012 Apr;132(2):429-37
pubmed: 21614565
Blood. 2008 Jan 15;111(2):856-64
pubmed: 17942756
Cell Physiol Biochem. 2018;47(1):368-377
pubmed: 29772566
Epigenomics. 2014;6(6):651-64
pubmed: 25531258
Cancer Res. 2006 Apr 15;66(8):4095-9
pubmed: 16618729
Onco Targets Ther. 2019 Jun 17;12:4683-4690
pubmed: 31354300
BMC Med Inform Decis Mak. 2005 Aug 08;5:25
pubmed: 16086837
Blood. 2005 May 15;105(10):4060-9
pubmed: 15677557
Onco Targets Ther. 2019 Mar 14;12:1965-1977
pubmed: 30936716